HIV viremia and changes in kidney function

AIDS

Volumn 23, Issue 9, 2009, Pages 1089-1096

  Longenecker, Chris T ^a   Scherzer, Rebecca ^a,b   Bacchetti, Peter ^a   Lewis, Cora E ^c   Grunfeld, Carl ^a,b,d   Shlipak, Michael G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cystatin C; Glomerular filtration rate; HIV; Kidney; Viral load

Indexed keywords

CYSTATIN C; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; TENOFOVIR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; VIREMIA;

EID: 67651094205     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832a3f24     Document Type: Article

References (34)

1. Humphreys MH. Human immunodeficiency virus-associated glomerulosclerosis. Kidney Int 1995; 48:311-320.
2. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-546.
3. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145-1152.
4. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. The impact of HIV on chronic kidney disease outcomes. Kidney Int 2007; 72:1380-1387.
5. Wyatt CM, Morgello S, Katz-Malamed R, Wei C, Klotman ME, Klotman PE, D'Agati VD. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int 2009; 75:428-434.
6. Fernando SK, Finkelstein FO, Moore BA, Weissman S. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci 2008; 335:89-94.
7. Cheung CY, Wong KM, Lee MP, Liu YL, Kwok H, Chung R, et al. Prevalence of chronic kidney disease in Chinese HIV-infected patients. Nephrol Dial Transplant 2007; 22:3186-3190.
8. Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, Moore RD. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007; 21:2435-2443.
9. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, et al. Chronic renal failure among HI V-1-infected patients. AIDS 2007; 21:1119-1127.
10. Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, et al. Microalbuminuria in HIV infection. AIDS 2007; 21:1003-1009.
11. Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, Shlipak MG. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med 2007; 167:2213-2219.
12. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22:481-487.
13. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM. Performance of the modification of diet in renal disease and Cock-croft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005; 16:459-466.
14. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40:221-226.
15. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, Warram JH. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005; 16:1404-1412.
16. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Newman AB, Siscovick DS, et al. Rate of kidney function decline in the elderly: a comparison using creatinine and cystatin C. Am J Nephrol 2009: (in press).
17. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51:395-406.
18. Jones CY, Jones CA, Wilson IB, Knox TA, Levey AS, Spiegelman D, et al. Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study. Am J Kidney Dis 2008; 51:914-924.
19. Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TW, Prokopowicz D, Rogalska M, Parfieniuk A. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. Antivir Ther 2006; 11:641-645.
20. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006; 163:860-869.
21. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41:1105-1116.
22. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 1999; 59:1-8.
23. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2006; 17:254-261.
24. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008; 168:2212-2218.
25. Kosmiski LA, Bacchetti P, Kotler DP, Heymsfield SB, Lewis CE, Shlipak MG, et al. Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab 2008; 93:216-224.
26. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999; 8:3-15.
27. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000; 56:779-788.
28. Ross MJ, Klotman PE. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol 2002; 13:2997-3004.
29. Ifudu O, Rao TK, Tan CC, Fleischman H, Chirgwin K, Friedman EA. Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am J Nephrol 1995; 15:217-221.
30. Reid A, Stohr W, Walker AS, Williams IG, Kityo C, Hughes P, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008; 46:1271-1281.
31. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
32. Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, et al. Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS 2009; 23:71-82.
33. Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 2004; 15:3184-3191.
34. Berns JS, Kasbekar N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 2006; 1:117-129.